|D011024||Pneumonia, Viral NIH||0.11|
There is one clinical trial.
Randomized open label clinical trial carried out at study centers in Sweden, including Karolinska University Hospital, S:t Göran Hospital, Danderyd Hospital and Västmanlands Hospital. Patients with COVID-19 who are hospitalized with oxygen therapy are eligible for inclusion. Subjects are randomized to 14 days of inhalation with ciclesonide 360 µg twice daily or to standard of care. Primary outcome is duration of received supplemental oxygen therapy. Key secondary outcome is a composite outcome of death and received invasive mechanical ventilation within 30 days.
Description: Time (in days) of received supplemental oxygen therapy (defined as being alive and discharged from hospital to home or at least 48 h of not receiving oxygen therapy during hospitalization).Measure: Duration of received supplemental oxygen therapy Time: 30 days after study inclusion
Description: Rate of and time to (in days) received invasive mechanical ventilation or all-cause deathMeasure: Invasive mechanical ventilation or all-cause death (key secondary outcome) Time: 30 days after study inclusion
Description: Rate of and time to (in days) death of any causeMeasure: All cause death Time: 30 days after study inclusion
Description: Rate of and time to (in days) received invasive mechanical ventilationMeasure: Invasive mechanical ventilation Time: 30 days after study inclusion
Description: Level of remaining dyspnea symptoms according to the Modified Medical Research Council Dyspnea ScaleMeasure: Remaining dyspnea symptoms Time: 30-35 days and 5-7 months after inclusion
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports